Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial – protocol of a multicenter, randomized, double-blind, placebo-controlled proof-of-concept phase-2 clinical trial

HIGHLIGHTS

• who: Petra Huehnchen from the University of Florence, Italy have published the Article: Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial - Protocol of a multicenter, randomized, double-blind, placebo-controlled proof-of-concept phase-2 clinical trial, in the Journal: (JOURNAL) of 11/08/2022
• what: The aim of this proof-of-concept phase-2 clinical trial is to test the hypothesis, that a co-medication with oral lithium carbonate (Quilonum retard), adjusted to target lithium serum levels of 0.5-0.8 mmol/l, is able to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.